Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients

Journal of Hepatology

Volumn 28, Issue 2, 1998, Pages 280-291

  Kurszynska, Yolanta T ^a   Goulas, Spiros ^b   Wollen, Nigel ^b   McIntyre, Neil ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

C peptide; Cirrhosis; Diabetes; Glucagon; Hyperglycemic glucose clamp; Insulin

Indexed keywords

ARGININE; C PEPTIDE; GLUCAGON; INSULIN;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0032006528     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-8278(88)80015-1     Document Type: Article

References (63)

1. Kurszynska YT, McIntyre N., Alberti KGMM, Krall LP. Glucose intolerance and diabetes in liver disease. Marshall SM, Home PD. The Diabetes Annual. 1993;7.55-7.82 Elsevier Science Publishers, Amsterdam.
2. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. ii:1967;1051-1056.
3. Kurszynska YT, Home PD, McIntyre N. The relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology. 14:1991;103-111.
4. Kurszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia. 36:1993;121-128.
5. Kruszynska YT, Munro J, Home PD, McIntyre N. Twenty-four hour C-peptide and insulin secretion rates and diurnal profiles of glucose, lipids and intermediary metabolites in cirrhosis. Clin Sci. 83:1992;597-605.
6. Petrides A, Vogt C, Schulz-Berge D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 19:1994;616-627.
7. Kurszynska YT, Harry Ds, Mohamed-Ali V, Home PD, Yudkins JS, McIntyre N. The contribution of proinsulin and des-31,32proinsulin to the hyperinsulinaemia of diabetic and non-diabetic cirrhotic patients. Metabolism. 44:1995;254-260.
8. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished B cell secretory capacity in patients with non-insulin-dependent diabetis mellitus. J Clin Invest. 74:1984;1318-1328.
9. Van Haeften TW, Van Maarschalkerweerd WA, Gerich JE, Van der Veen EA. Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM. Eur J Clin Invest. 21:1991;168-174.
10. Stefan Y, Orci L, Malaisse-Lagae F, Perrelet A, Patel Y, Unger RH. Quantitation of endocine cell content in the pancreas of non-diabetic and diabetic humans. Diabetes. 31:1982;694-700.
11. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, et al. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetis Metab Rev. 3:1987;307-332.
12. Sherwin RS, Fisher M, Bessoff J, Snyder M, Hendler R, Conn HO, et al. Hyperglucagonaemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology. 74:1978;1224-1228.
13. Dudley FJ, Alford FP, Chisholm DJ, Findlay DM. Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: paired studies of pre- and post-shunted subjects. Gut. 20:1979;817-824.
14. Keller U, Sonneberg GE, Burckhardt D, Perruchoud A. Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver. J Clin Endocrinol Metab. 54:1982;961-968.
15. Fabbri A, Marchesini G, Bianchi G, Bugianesi E, Bortoluzzi L, Zoli M, et al. Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: dependence on liver cell failure. Hepatology. 18:1993;28-35.
16. McDonald TJ, Dupre J, Caussignac Y, Radziuk J, Van Vliet S. Hyperglucagonaemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels. Metabolism. 28:1979;300-307.
17. Smith-Laing G, Orskov H, Gore MBR, Sherlock S. Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage. Diabetologia. 19:1980;103-108.
18. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetis. Response to carbohydrate and protein ingestion. N Engl J Med. 283:1970;109-115.
19. Raskin P, Aydin I, Yamamoto T, Unger RH. Abnormal alpha cell function in human diabetis. The response to oral protein. Am J Med. 64:1978;988-997.
20. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonaemia in maintenance of increased rates of hepatic glucose output in type II diabetis. Diabetes. 36:1987;274-283.
21. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes. 39:1990;1381-1390.
22. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes. 33:1984;486-494.
23. WHO Study Group. Diabetis mellitus. Technical Report Series 727. WHO. 1985;80-82.
24. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique. A method for quantifying insulin secretion and resistance. Am J Physiol. 237:1979;E214-E223.
25. Soelder JS, Sloane D. Critical variables in the radioimmunoassay of serum insulin using the doubly-antibody technic. Diabetes. 14:1965;771-779.
26. Wallum BJ, Kahn SE, McCulloch DK, Porte D. Insulin secretion in the normal and diabetic human. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P. International Textbook of Diabetes Mellitus. 1992;285-301 Wiley & Sons, Chichester.
27. Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D. Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab. 65:1987;59-64.
28. Ward WK, Halter JB, Beard JC, Porte D. Adaptation of B and A cell function during prolonged glucose infusion in human subjects. Am J Physiol. 246:1984;E405-E411.
29. Logothetopoulos J, Kaneko M, Wrenshall GA, Best CH. Zinc, granulation and extractable insulin of islet cells following hyperglycaemia or prolonged treatment with insulin. Brolin SE, Hellman B, Knutson H. The structure and metabolism of the pancreatic islets. 1964;333-347 Pergamon Press, Oxford, UK.
30. Kruszynska YT, Villa-Komaroff L, Halban PA. Islet B-cell dysfunction and the time course of recovery following chronic overinsulinsation of normal rats. Diabetologia. 31:1988;621-626.
31. Kruszynska YT, Olefsky JM. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med. 44:1996;413-428.
32. Ward WK, Johnston CL, Beard JC, Bendetti TJ, Halter JB, Porte D. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes. 34:1985;861-869.
33. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetis mellitus. J Clin Invest. 95:1995;690-698.
34. Johnson C, Ward WK, Beard JC, McKnight B, Porte D. Islet cell function and insulin sensitivity in the non-diabetic offspring of conjugal type 2 diabetic patients. Diabetic Med. 7:1990;119-125.
35. Marco J, Diego J, Villaneuva ML, Diaz-Fierros M, Valverde I, Segovia JM. Elevated plasma glucagon levels in cirrhosis of the liver. N Engl J Med. 28:1973;1107-1111.
36. Sherwin RS, Bastl C, Finkelstein FO, Fischer M, Black H, Hendler R, et al. Influence of uraemia and haemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest. 57:1976;722-731.
37. Jaspan JB, Rubenstein AH. Circulating glucagon. Plasma profiles and metabolism in health and disease. Diabetis. 26:1977;887-904.
38. Bastl C, Kinkelstein FO, Sherwin R, Hendler R, Felig P, Hayslett JP. Renal extraction of glucagon in rats with normal and reduced renal function. Am J Physiol. 233:1977;F67-F71.
39. Blackard WG, Nelson NC, Andrews SS. Portal and peripheral vein immunoreactive glucagon concentrations after arginine or glucose infusions. Diabetes. 23:1974;199-202.
40. Jaspan JB, Polonsky KS, Lewis M, Pensler J, Pugh W, Moossa AR, et al. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 240:1981;E233-E244.
41. Kabadi UM, Eisenstein AB, Tucci J, Pellicone J. Hyperglugonaemia in hepatic cirrhosis: its relation to hepatocellular dysfunction and normalization on recovery. Am J Gastroenterol. 79:1984;143-149.
42. Sjoberg RJ, Kidd GS. Pancreatic diabetis mellitus. Diabetes Care. 12:1989;715-724.
43. Larsen S, Hilsted J, Philipsen EK, Tronier B. The effect of insulin withdrawal on intermediary metabolism in patients with diabetes secondary to chronic pancreatitis. Acta Endocrinol. 124:1991;510-515.
44. Verrillo A, de Teresa A, Martino C, Pinto M, Golia R. Circulating somatostatin concentrations in healthy and cirrhotic subjects. Metabolism. 35:1986;130-135.
45. Kruszynska YT, Ghatei MA, Bloom SR, McIntyre N. Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. Hepatology. 21:1995;933-941.
46. Dupre J, Caussignac Y, McDonald TJ, Van Vliet S. Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonaemia. J Clin Endocrinol Metab. 72:1991;125-129.
47. Greco AV, Crucitti F, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG, et al. Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis. Diabetologia. 17:1979;23-28.
48. Starke A, Grundy S, McGarry JD, Unger RH. Correction of hyperglycaemia with phloridzin restores the glucagon response to glucose in insulin-dependent dogs: implications for human diabetes. Proc Natl Acad Sci USA. 82:1985;1544-1546.
49. Kruszynska YT, McIntyre N. Carbohydrate metabolism. McIntyre N, Benhamou PJ, Bircher J, Rizzetto M, Rizzetto M, Rodes J. Oxford Textbook of Clinical Hepatology. 1991;129-143 Oxford University Press, Oxford: UK.
50. Feruglio FS, Greco F, Cesano L, Colongo PG, Sardi G, Chiandussi L. The effects of glucagon on systemic and hepatosplanchnic haemodynamics and on net peripheral and hepato-splanchnic balance of glucose, latic and pyruvic acids in normal subjects and cirrhotics. Clin Sci. 30:1966;43-50.
51. Van Itallie TB, Bentley WB. Glucagon-induced hyperglycaemia as an index of liver function. J Clin Invest. 34:1955;1730-1737.
52. Petrides AS, DeFronzo RA. Failure of glucagon to stimulate hepatic glycogenolysis in well-nourished patients with mild cirrhosis. Metabolism. 43:1994;85-89.
53. Francavilla A, Jones AF, Starzl TE. Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis. Gastroenterology. 75:1978;1026-1032.
54. Del Prato S, Castellino P, Simonson DC, DeFronzo RA. Hyperglucagonaemia and insulin-mediated glucose metabolism. J Clin Invest. 79:1987;547-556.
55. Authier F, Desbuquois B, De Galle B. Ligand-mediated internalization of glucagon receptors in intact rat liver. Endocrinogy. 131:1992;447-457.
56. Honge G, Karsten O, Vintermyr K, Doskeland SO. The expression of cAMP-dependent protein kinase subunits in primary rat hepatocyte cultures. Cyclic AMP down-regulate its own effector system by decreasing the amount of catalytic subunit and increasing the mRNA's for the inhibitory (R) subunits of cAMP-dependent protein kinase. Mol Endocrinol. 4:1990;481-488.
57. Ferrannini E, Groop LC. Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev. 5:1989;711-725.
58. 13C nuclear magnetic resonance study. J Clin Invest. 90:1992;1323-1327.
59. Nurjhan N, Consoli A, Gerich JE. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetis mellitus. J Clin Invest. 89:1992;169-175.
60. Gerich JE, Lorenzi M, Schneider V, Karam JH, Rivier J, Guillemin R, et al. Effects on somatostatin on plasma glucose and glucagon levels in human diabetes mellitus: pathophysiologic and therapeutic implications. N Engl J Med. 291:1974;544-547.
61. Owen OE, Reichle FA, Mozzoli MA, Kreulen T, Patel MS, Elfenbein IB, et al. Hepatic, gut and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest. 68:1981;240-252.
62. Kruszynska YT, Meyer-Albert A, Darakhshan F, Home PD, McIntyre N. Metabolic handling of orally and administered glucose in cirrhosis. J Clin Invest. 91:1993;1057-1066.
63. Hamberg O, Vilstrup H. Effects of glucose on hepatic conversion of amino-nitrogen to urea in patients with cirrhosis: relationship to glucagon. Hepatology. 19:1994;45-54.